



## PRESS RELEASE

# FIDIA PHARMA GROUP HAS COMPLETED THE ACQUISITION OF SOOFT

*The acquisition gives an added boost to Fidia's leadership in the national and international ophthalmology market segment.*

Abano Terme (PD), June 11, 2018 – **Fidia Pharma Group**, an Italian multinational company, leader in the R&D, manufacturing and sales of a wide range of products mainly based on hyaluronic acid, announced today the closing of the acquisition of **Sooft**, #1 Italian ophthalmic company in Italy<sup>1</sup>, by acquiring Efil shareholders' remaining minority shares, thereby achieving 100% controlling ownership. With the closing of the transaction, which began in March 2017 and was finalized on terms agreed upon with the selling party, Fidia is pleased to report a solid business performance, underlying how, after one year since Sooft takeover, results are in line with expectations.

*«After one year of hard teamwork and determination – explains **Carlo Pizzocaro, President of Fidia Pharma Group** – aiming at reinforcing Fidia Pharma Group's ranking in the ophthalmology market segment, we are pleased to report that Sooft has fortified its position – revenues exceeded 70 million Euros - in a competitive and constantly evolving marketplace environment with interesting growth potential, and Fidia as a major key player in the Italian market».*

The completion of the operation will enable Fidia, who was active in the eye care segment in previous years, to consolidate its know-how and strengthen its role in this area, by including hi-tech, innovative products in its portfolio, a growth driver for the Group as a whole, both in national and international markets.

Sooft is active in the treatment of all major conditions that affect the eye, and operates through Sooft, Bioos, Glucom, OftaH.T. e Neoox trademarks. The company owns 27 patents, further bolstering Fidia Pharma Group's already strong portfolio, consisting of more than 900 patents, of which over 650 on hyaluronic acid with different molecular weights.

### **Fidia Farmaceutici**

*Fidia farmaceutici, part of Fidia Pharma Group, is a privately held, fully integrated Italian multinational company, with R&D, manufacturing, marketing and sales capabilities. The Company was founded in 1946 and is headquartered in Abano Terme (Italy), with R&D facilities both in Abano Terme and at the specialized Research Unit in Noto (Sicily). Fidia's overall objective is establishing its worldwide leadership in viscosupplementation, through an extensive product portfolio mainly based on hyaluronic acid (HA).*

---

<sup>1</sup> Source: IMS Data 2017

*Over 50 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of MW. The company holds more than 900 patents worldwide, of which over 650 involve hyaluronic acid.*

*Fidia Pharma Group's revenues accounted for 300 million Euros in 2017, over 50% generated in foreign markets. With strong local roots and an instinct for international growth, the Group extends its global reach in 100 countries worldwide, through local partners and distributors, as well as wholly-owned subsidiaries in attractive markets, such as USA, Germany, Spain, Russia, Czech and Slovak Republics and Middle East.*

**For more information, contact:**

[communication@fidiapharma.it](mailto:communication@fidiapharma.it)